

Angiotensin II-induced oxidative burst is fluvastatin sensitive in neutrophils of patients with hypercholesterolemia

Ildiko Seres*, Gabriella Fóris, Dénes Páll, Béla Kosztáczky,
Gyorgy Paragh Jr, Zsuzsa Varga, Gyorgy Paragh

First Department of Medicine, Medical and Health Science Center, University of Debrecen, H-4012 Debrecen, Hungary

Received 6 November 2004; accepted 29 March 2005

Abstract

The aim of this study was to investigate the effect of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor fluvastatin (Flu) on angiotensin II (AII)-stimulated neutrophils of patients with hypercholesterolemia. Results suggest that a 6-week-long Flu administration completely counteracted the AII-induced increase in superoxide anion and leukotriene C₄ production of the neutrophils of patients with hypercholesterolemia. However, the failure of signal processing through pertussis toxin-sensitive G protein, the increase in [Ca²⁺]_i in membrane-bound protein kinase C activity, and the increase in neutrophil-bound cholesterol content were only partially restored by Flu. In addition, Flu had no effect on the increased membrane rigidity of the neutrophils of patients with hypercholesterolemia. To sum it up, Flu administration had a beneficial effect on AII-triggered reactive oxygen species generation; it resulted in partial restoration of signaling processes and of membrane composition, but membrane fluidity remained unchanged.

© 2005 Elsevier Inc. All rights reserved.

1. Introduction

In our previous publications, we described that angiotensin II (AII) could activate human neutrophils of control subjects and patients with hypercholesterolemia (HC) through different intracellular signaling pathways. The AII-induced superoxide anion and leukotriene C₄ (LTC₄) generation was significantly higher in neutrophils of patients with HC than in those of healthy subjects [1]. In this study, we investigated the possible beneficial effect of fluvastatin (Flu) on AII-stimulated neutrophils of healthy volunteers. One of the effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor statins against atherosclerosis is their antioxidant feature. Various statins are able to inhibit nicotinamide adenine dinucleotide phosphate (NADPH) oxidase to a different extent through the inhibition of the isoprenoid pathway [2]. The NADPH oxidase, which is the key enzyme of superoxide anion production in neutrophils, is regulated by Rac2 guanosine triphosphatase (GTPase) from the Rho family, which is activated by the mevalonate cycle through geranylgeranylation [3–5]. At the same time,

AII plays a role in the pathomechanism of atherosclerosis, not only as a hypertension-inducing neurohormone but also through its oxidative burst-triggering ability [6–9]. In addition, on the site of plaque formation, the local production of AII is increased and AII type 1 (AT1) receptors are up-regulated [10].

Furthermore, our studies have shown that in human neutrophils of individuals with hyperlipidemia, the chemotactic peptide formyl-Met-Leu-Phe and AII were unable to induce either Ins(1,4,5)P₃ (IP₃) generation or Ca²⁺ signals from intracellular pools despite the intensive production of superoxide anion and leukotrienes [1,11].

The goals of the present study were (1) to determine the possible beneficial effect of a 6-week-long Flu treatment on the pathological release of oxidizing agents by neutrophils of patients with HC and (2) to evaluate whether Flu administration is able to restore the disturbed signaling pathway and membrane status.

2. Methods

2.1. Patients

We enrolled 28 male patients with type IIa HC who were not to receive any treatment, 21 male patients with HC

* Corresponding author. Tel.: +36 52 414 227; fax: +36 52 442 101.
E-mail address: forisg@jaguar.dote.hu (G. Fóris).

Table 1

Demographic data of investigated control subjects and Flu-treated and nontreated patients with HC

| Parameters | Control subjects (n = 34) | Patients with HC (n = 28) | Patients with HC + Flu ^a (n = 21) |
|--------------------------------------|------------------------------|------------------------------|--|
| Age (y) | 58.2 ± 6.3 | 55.7 ± 6.0 | 59.2 ± 6.87 |
| Body mass index (kg/m ²) | 23.8 ± 3.2 | 22.6 ± 3.5 | 24.1 ± 3.8 |
| WHR ^b | 0.86 ± 0.11 | 0.95 ± 0.15 | 0.92 ± 0.13 |
| Cholesterol (mmol/L) | 4.6 ± 0.51 | 8.7 ± 1.0 | 5.9 ± 0.68 ^c |
| Triglyceride (mmol/L) | 1.7 ± 0.22 | 1.9 ± 0.24 | 1.7 ± 0.20 |
| HDL cholesterol (mmol/L) | 1.35 ± 0.15 | 1.31 ± 0.15 | 1.40 ± 0.16 |
| LDL cholesterol (mmol/L) | 3.43 ± 0.41 | 6.72 ± 0.78 | 4.11 ± 0.55 ^c |

Each value represents the mean ± SD.

^a The following data represent Flu administration's favorable results after 6 weeks: decrease in cholesterol, 17.4; in LDL-C, 26.6; in apolipoprotein B100, 18.3; and in LDL/HDL, 28.1%.

^b Waist hip ratio.

^c Differences between Flu-treated and nontreated groups of patients are significant ($P < .01$).

treated for 6 weeks with 40 mg/d of Flu (Lescol, Novartis, Budapest, Hungary), and 34 age-matched healthy male volunteers. In the patients with HC, both low-density lipoprotein (LDL) receptor failure and familial origin were excluded. Patients as well as control volunteers were kept on a National Cholesterol Education Program step I diet. The demographic data of the investigated subjects are summarized in Table 1. The effect of Flu was not studied on the same group of patients with HC (ie, the experiment was not self-controlled). In the Flu-treated HC group, the changes in lipid parameters were as follows: plasma total cholesterol, −17.4%; high-density lipoprotein (HDL) cholesterol, +5.9%; triglycerides, −9.6%; apolipoprotein A1, +6.2%; apolipoprotein B100, −18.3%; LDL/HDL, −28.1%; LDL cholesterol, −24.6%. Exclusion criteria were liver, thyroid, and kidney diseases; diabetes mellitus; infective disorders; fever; and lipid-lowering medication use. A Cobas Integra 700 Analyzer (Roche, Basel, Switzerland) was used for lipid measurements. The LDL cholesterol fraction was calculated indirectly using the Friedewald equation. Apolipoprotein examination was performed with an immunonephelometric assay in which an Orion Diagnostic kit (Orion Diagnostica, Espoo, Finland) was used. Venous blood samples (10–15 mL) were taken from healthy volunteers and patients at intervals of 4 to 5 days for each set of experiment. All determinations were carried out parallel in each patient group instead of using a self-controlled system. The study protocol was approved by the local ethics committee of the Medical and Health Science Center, University of Debrecen, and informed consent was obtained from all patients.

2.2. Isolation of neutrophils

Neutrophils were separated by Ficoll-Hypaque density gradient centrifugation according to the method of Boyum [12]. The cell suspensions were 95% pure for neutrophils as judged by morphological criteria, and 96% were viable.

2.3. Culture conditions

Cell suspensions were performed in a serum-free Hanks balanced salt solution (HBSS) with the appropriate cell densities. All incubations were carried out in an ASSAB CO₂ incubator (humidity, 95%; air, 95%; CO₂, 5%) at 37°C. For in vitro stimulation of neutrophils, AII (Serva, Heidelberg, Germany) was used, and as we described previously, the appropriate immunostimulating concentration was determined by the intracellular killing measurement [1,8,9]. Based on these experiments, 10 nM of AII was the most effective concentration to stimulate human neutrophils. In some experiments, neutrophils at 10⁶/mL density were preincubated with different inhibitory drugs before AII stimulation. These were 7.5 nmol/mL of pertussis toxin (PT) (Calbiochem, La Jolla, Calif) for 120 minutes, 1.0 μM of Ca²⁺ channel-blocking verapamil (V, Sigma Co, St Louis, Mo) for 60 minutes, and 1.0 μM of phospholipase A₂ (PLA₂) inhibitory mepacrin (M, Sigma) for 60 minutes. We applied the above concentrations based on our previous studies and, in part, on the literature [13–17].

2.4. Superoxide anion generation

The O₂[−] was measured as we previously described in detail [18]. To briefly sum it up, the determination was carried out spectrophotometrically by measuring the reduction of cytochrome C (type IV, Sigma), according to the method of Babior et al [19], in a microassay using a 96-well microplate and an ELISA reader (Anthos Labtec, Wien, Austria). Neutrophils were stimulated with AII at a final concentration of 10 nM. Each experiment was performed in triplicate. Results were expressed as nanomoles of produced O₂[−] per 30 minutes per 10⁶ neutrophils.

2.5. Measurement of LTC₄

The leukotriene synthesis of neutrophils was determined according to the method of Jubiz et al [20] with slight modifications. Leukotriene C₄ (Sigma) was applied as internal standard. After the preincubation of the neutrophils (at 10⁷ polymorphonuclear leukocytes/mL density) with different inhibitory drugs as described above, they were stimulated under constant stirring with 10 nM of AII in a CO₂ incubator at 37°C. As in our earlier experiments, LTC₄ production was the most pronounced among all leukotrienes triggered by AII. Therefore, only LTC₄ determination was performed (at 280 nm), as described previously [10]. Data were processed using a model of D-6000 HPLC Manager Software (Merck, Darmstadt, Germany).

2.6. Determination of IP₃

Determination of IP₃ was carried out according to the method of Shaymann and BeMeut [21]. An aliquot of neutrophil suspension (10⁷ cells/mL) in HEPES-buffered HBSS was incubated for 4 hours at 37°C in the presence of 100 to 200 μCi of myo-[³H]inositol (Amersham, Braunschweig, Germany) and 10 nmol/L of LiCl using a CO₂

incubator equipped with a shaker. The appropriate concentrations of inhibitory drugs were added to the aliquots of this mixture 10 to 120 minutes before the completion of preincubations with *myo*-[^3H]inositol. After vigorous washing, cell-bound radioactivity was determined. The incorporated *myo*-[^3H]inositol was at least 50% of the total applied radioactivity even in the presence of inhibitory drugs in the samples. Neutrophils were stimulated with 10 nM of AII, and after 2 minutes, the reaction was terminated with ice-cold perchloric acid and neutralized with saturated KHCO_3 . $\text{Ins}(1,4,5)\text{P}_3$ was isolated by reversed-phase ion-pair chromatography using IP_3 as internal standard (Amersham). The amount of produced IP_3 was expressed as a percentage of disintegrations per minute to the corresponding disintegrations per minute of resting neutrophils.

2.7. Measurement of $[\text{Ca}^{2+}]_i$

$[\text{Ca}^{2+}]_i$ was determined as described by McCormach and Cobbold [22] by using Indo 1/AM (Calbiochem) as described earlier [1,11]. The determination of $[\text{Ca}^{2+}]_i$ was carried out in a spectrofluorometer (Hitachi F-4500, Hitachi, Ltd, Tokyo, Japan) at 405 and 485 nm under constant stirring at 37°C. Neutrophils were stimulated with 10 nM of the final concentration of AII during measurements. In some experiments, neutrophils were preincubated with inhibitory drugs before the addition of 20 nmol of Indo 1/AM to 10^7 cells. The resultant dye intake was not altered by the preincubations. The peak of $[\text{Ca}^{2+}]_i$ increase occurred after stimulation for 100 to 200 seconds in all experimental groups. The $[\text{Ca}^{2+}]_i$ was calculated according to the indicated equation. The Ca^{2+} signals were expressed as peak $[\text{Ca}^{2+}]_i$ minus the $[\text{Ca}^{2+}]_i$ of nonstimulated resting neutrophils in nanomolars of Ca^{2+} .

2.8. Measurement of protein kinase C activity

The measurement was carried out via the method of Bell et al [23] modified by Gopalakrishna et al [24]. The freshly isolated neutrophils' suspension (5×10^6 cells) was centrifuged at 4°C. The pellets were resuspended in HEPES-buffered ice-cold HBSS containing EDTA, 0.5 mmol/L of EGTA, phenylmethyl-sulfonylfluoride (Sigma), and leupeptin (Sigma). Cells were disrupted ultrasonically (Branson Sonifier 450, Branson Ultrasonic Corp, Danbury, Conn) and centrifuged at 100000 g for 45 minutes at 4°C (Beckman L-5-65B, Palo Alto, Calif). Both the supernatants containing cytosol and the pellets were then solubilized with CHAPS (Sigma) and 1% Nonidet P-40 (Sigma). The pellets were rehomogenized and centrifuged again as mentioned above. The protein kinase C (PKC) activities of cytosolic and membrane fractions were determined by measuring the ^{32}P incorporation from 100 to 200 cpm/mg gamma [^{32}P]-ATP (Institute of Radiochemical Research, Budapest, Hungary) into 100 $\mu\text{g}/\text{mL}$ histone III-S (Sigma). The reaction was terminated after 10 minutes by adding ice-cold trichloroacetic acid and bovine serum albumin as a carrier. The precipitate was then filtered through a 0.45- μm

Millipore HA filter (Millipore, Bedford, Mass) and washed in $5 \times 2 \text{ mL}$ ice-cold trichloroacetic acid. The radioactivity was determined with a Packard 2200 CA liquid scintillation counter (Packard, Meriden, Conn), using a toluol cocktail to dissolve the filter. The PKC activity was expressed as incorporated ^{32}P picomoles per minute per milligram of protein.

2.9. Measurement of cell cholesterol

Cholesterol content was measured by the method of Goh et al [25]. Neutrophils (10^7 cells/mL) were digested in a solution containing 0.1% sodium dodecyl sulfate (Sigma), 1 mmol/L EDTA (Sigma), and 0.1 mol/L Tris buffer, pH 7.4, at 30°C for 5 minutes. The gelatinous mixture was homogenized by discharging it 5 times through a 21-G needle attached to a 3-mL syringe. To a 400- μL aliquot of appropriately diluted cell digest, a 100- μL mixture containing 150 mmol/L of sodium phosphate, pH 7, 30 mmol/L of sodium taurocholate, 1.02 mmol/L of polyethylene glycol (molecular weight, 8000), 0.2 U of cholesterol oxidase (Sigma), 0.4 U of horseradish peroxidase type IV (Sigma), and 0.4 mg of *P*-hydroxyphenylacetic acid was added. The mixture was incubated for 60 minutes at 30°C. Two milliliters of 50-mmol/L sodium phosphate, pH 7.4, was added after the incubation period. Sample fluorescence was determined at an excitation wavelength of 360 nm and an emission wavelength of 405 nm using a Hitachi F-4500 spectrofluorometer.




Fig. 1. The inhibition of AII-triggered superoxide anion generation of neutrophils obtained from control subjects and from nontreated and Flu-treated patients with HC. Each value represents the mean \pm SD. (a) Differences of the AII-triggered increase in superoxide anion production between the control and HC groups are significant ($P < .001$). (b) Inhibition of AII-induced superoxide anion production in the HC group after Flu treatment is significant ($P < .001$). (c) Difference between the control and HC + Flu-treated groups is not significant ($P = .3293$). (d) Inhibition by in vitro preincubation is significant ($P < .001$).




Fig. 2. Inhibition of AII-triggered LTC₄ production of neutrophils obtained from control subjects and from nontreated and Flu-treated patients with HC. Each value represents the mean \pm SD. (a) Differences of AII-triggered increase in LTC₄ production between the control and HC groups are significant ($P < .001$). (b) Inhibition of AII-induced LTC₄ production in the HC group after Flu treatment is significant ($P < .001$). (c) Difference between the control and HC + Flu-treated groups is not significant ($P = .4895$). (d) Inhibition by in vitro preincubation is significant ($P < .001$).

2.10. Determination of membrane fluidity

The membrane fluidity was measured by fluorescence polarization, according to the method of Shinitzky and Yuli [26], using dimethylhexatriene (Sigma). The diphenylhexatriene dispersion (2.15 μ mol/L) was mixed with 5×10^6 cell/mL of HBSS in a 1:1 proportion, followed by a 30-minute incubation in the dark. After washing the cells, they were analyzed for fluorescence polarization in a spectrofluorometer (Hitachi F-4500) equipped with a polarization attachment and thermostatic cell holder. The extinction was carried out at 355 nm and the emission at 430 nm was determined. The obtained polarization value (P) is inversely proportional to the fluidity of the cell membrane.

2.11. Statistical analysis

For mathematical analysis, paired and unpaired t tests with Welch's correction, analysis of variance, the Student-Newman-Keuls (SAS 6.12 program) test, and the GraphPad Software Prism Version 2.0 One-Side Binding Hyperbola (GraphPad Software, San Diego, Calif) program were applied.

Table 2

Angiotensin II-induced elevation of IP₃ production and its inhibition in neutrophils obtained from control subjects and from Flu-treated and nontreated patients with HC

| Incubations | Control subjects | | Patients with HC | | Patients with HC + Flu | |
|-------------|-------------------------------|-------|------------------|-------|-------------------------------|-------|
| | Values \pm SD | P | Values \pm SD | P | Values \pm SD | P |
| None | 100.0 \pm 18.2 | | 112.2 \pm 18 | | 103.9 \pm 25.5 | |
| AII | 221.5 \pm 50.1 ^a | <.001 | 118.6 \pm 14.8 | .3755 | 175.7 \pm 29.5 ^a | <.001 |
| PT + AII | 125.1 \pm 40.2 ^b | <.001 | 117.0 \pm 13.0 | .4974 | 169.9 \pm 33.2 ^b | .6613 |

Values were calculated as percentage of IP₃ in nonstimulated neutrophils of control subjects.

^a Differences between the nonstimulated (none) and AII-stimulated groups.

^b Differences between the AII-stimulated and PT-inhibited groups.

3. Experimental results

Fig. 1 shows that AII induced a significantly higher O₂⁻ production in neutrophils of patients with HC than in those of control volunteers. However, Flu treatment abolished this enhanced oxidative burst. In neutrophils obtained from healthy subjects, the AII-triggered superoxide production was inhibited by pretreatment with G protein-inhibiting PT, but inhibition of Ca²⁺ channel opening and PLA₂ activity by V and M preincubations appeared to be ineffective. In contrast, V and M inhibited the AII-triggered enhanced superoxide release of neutrophils of patients with HC successfully. In the patient group, the AII-induced superoxide production was normalized after Flu administration, but superoxide production could be inhibited similarly to the nontreated HC group by V and M. These results suggest that Flu is not able to restore the altered signaling pathways of AII stimulation in neutrophils of patients with HC. Furthermore, an intensive AII-triggered LTC₄ production was measured in the control and patient groups, and the LTC₄ synthesis was more pronounced in the latter cases. The increase in AII-triggered LTC₄ production was completely counteracted by Flu treatment (Fig. 2). Our results obtained after preincubation with different inhibitory drugs seemed to be similar to those obtained in the case of superoxide anion production. In neutrophils of control subjects, the AII-triggered LTC₄ production was inhibited by in vitro pretreatment with PT, whereas in neutrophils of patients with HC—both in the nontreated and Flu-treated groups—the intensive LTC₄ production was inhibited by V and M. Based on these results, the beneficial effect of Flu administration on the oxidative processes of the neutrophils of patients with HC does not seem to affect the signaling pathways. To clarify this issue, the direct effect of Flu administration on AII-stimulated IP₃ elevation was assessed (Table 2). The IP₃ signaling in neutrophils of control subjects was PT sensitive, whereas AII induced a complete failure of IP₃ signaling in the cells of the HC group. The failed IP₃ signal in the HC group was in part restored by Flu administration, and this IP₃ signal appeared to be PT resistant. The increase in [Ca²⁺]_i (ie, the Ca²⁺ signals in neutrophils obtained from control subjects and patients with HC) with and without Flu administration is shown in Fig. 3. It should be noted that in resting cells obtained from patients with HC, the [Ca²⁺]_i level was significantly increased




Fig. 3. Inhibition of AII-induced increase in δ -[Ca²⁺]_i (ie, Ca²⁺ signal of neutrophils obtained from control subjects and nontreated and Flu-treated patients with HC). Each value represents the mean \pm SD. (a) Decrease in AII-induced Ca²⁺ signal between the control and HC groups is significant ($P < .001$). (b) Restoration of AII-induced Ca²⁺ signal in the Flu-treated group is significant ($P < .001$). (c) Inhibition of Ca signal by in vitro preincubation is significant ($P < .001$). The single asterisk indicates that differences are significant between the values in the control and HC groups ($P < .001$); double asterisk, values differ significantly from the values in the control and HC groups ($P < .001$).

compared with control subjects, and Flu was only partially able to restore the normal level of [Ca²⁺]_i. The Ca²⁺ signal elicited by AII in neutrophils of patients with HC was lower than that in those of control subjects, but Flu treatment counteracted this decrease in the intensity of the Ca²⁺ signal ($P < .001$). The Ca²⁺ signal in neutrophils of control subjects triggered by AII was only inhibited by pretreatment with PT. In neutrophils of patients with HC, the signal was inhibited after in vitro treatment with V and M. The Ca²⁺ signal was inhibited in the HC + Flu group not only by V and M but also partially by PT pretreatment ($P = .0356$). Furthermore, the action of another key enzyme of signal processing—the PKC activity—was also studied in resting neutrophils and showed that the membrane-bound PKC activity increased in the untreated and Flu-treated HC

groups (Table 3). Although Flu treatment was able to significantly ($P < .001$) decrease the membrane-bound PKC activity, the enzyme activity did not return to normal levels. The cell-bound cholesterol content and membrane fluidity were also measured in resting neutrophils. The cell-bound cholesterol increased significantly in neutrophils of nontreated patients with HC, whereas administration of Flu resulted in partial restoration of cholesterol in the neutrophils' membranes. Despite the fact that Flu induced a decrease in serum and cell-bound cholesterol content, the increased membrane rigidity in the HC group was not restored by Flu administration.

4. Discussion

The practical importance of the present study was to see whether AII's atherosclerosis promoting effect could be counteracted by statin administration. Angiotensin II can stimulate reactive oxygen species and has an inhibiting effect on the scavenging system. The amount of locally produced AII at the site of injured intima is uncertain for the following reasons: (1) AII is produced by systems that are independent from the renin-angiotensin system at the site of injury and the locally generated AII induces an up-regulation of AT1 receptors [27–29] and (2) AII has a concentration-dependent biphasic effect on neutrophils, and—based on our earlier studies—the neutrophils of patients with HC react more intensively to AII stimulation than those of control subjects [1].

According to our recent results, Flu counteracts the AII-induced enhanced production of superoxide anion and LTC₄ of neutrophils of patients with HC. This benefit of Flu administration may occur through its inhibitory effect on the activation of the Rac2 GTPase, which is a member of the Rho family and is involved in both NADPH oxidase and PLA₂ activation [30,31]. Regarding the reason of the absent IP₃ signal in neutrophils of patients with HC (Table 2), we may not exclude the possibility of HC-induced alterations of other kinases. These kinases, such as phosphatidylinoside-3-kinase (PI3K), phosphatidylinoside-4-kinase, and MAP kinase, are involved in the regulation of G protein-binding receptor signaling, which differs from the so-called canonical PI pathway [32–34]. It should be pointed out that our knowledge on the signaling of G protein-binding receptors

Table 3

Effect of Flu treatment on PKC activity, cell-bound cholesterol content, and fluorescence polarization (P) of diphenylhexatriene in neutrophils obtained from control subjects and nontreated and Flu-treated patients with HC

| Parameters | Control subjects | Patients with HC | Patients with HC + Flu |
|---|--------------------|----------------------------------|----------------------------------|
| Membrane-bound PKC ^a | 243.5 \pm 41.3 | 2089 \pm 482.5 ^b | 683.4 \pm 199.2 ^c |
| Cell-bound cholesterol (μ g/10 ⁷ cells) | 4.579 \pm 0.835 | 9.658 \pm 2.136 ^b | 6.273 \pm 1.865 ^c |
| Fluorescence (polarization of dimethylhexatriene) | 0.3998 \pm 0.011 | 0.6115 \pm 0.0673 ^b | 0.6811 \pm 0.1279 ^d |

Each value represents mean \pm SD.

^a Protein kinase C activity is expressed as incorporated ³²P per minute per milligram of protein.

^b Differences between the control and HC groups are significant ($P < .001$).

^c Differences between the control and HC + Flu groups and between HC and HC + Flu groups are significant ($P < .001$).

^d Differences between the control and HC + Flu groups are significant, whereas between the HC and HC + Flu groups, the P value was .4099.

under pathological circumstances is incomplete, particularly in the case of AT1 receptors [35–37]. The partial restoration of IP₃ signals after Flu administration occurred through a PT-resistant pathway, whereas in the Flu-treated group, the AII-triggered Ca²⁺ signal originated through a mixed pathway either from intracellular pools or from the extracellular medium (Fig. 3). The increased amount of membrane-bound PKC in resting neutrophils of patients with HC may be the consequence of new PKC isoforms,

which appear in the cell membrane. In normal human neutrophils, the ϵ , α , and β isoforms are present, whereas PKC ϵ , PKC ζ , and PKC δ may also appear in the case of altered membrane functions [38].

As we described earlier, AII activates the Gi protein and phospholipase C (PLC), which can be inhibited with PT, through its AT1 receptors in neutrophils of control subjects. The produced IP₃ triggers Ca²⁺ signal from intracellular pools, whereas diacylglycerol activates PLA₂ and leukotriene




Fig. 4. One of the possible signaling pathways through AT1 receptors in neutrophils of patients with HC (A) and Flu-treated patients (B). AA indicates arachidonic acid cascade; AII-R, angiotensin II receptor; IP₃(1,4,5), Ins(1,4,5)P₃; IP₃(3,4,5), Ins(3,4,5)P₃; m, membrane bound; Mev, mevalonate.

synthesis. Furthermore, Ca^{2+} signal and diacylglycerol cause PKC activation and translocation into the membrane [39]. According to our recent and earlier findings, in neutrophils of patients with HC, the increase in free radical generation is caused by changes of intracellular signal transduction [1,14,39]. One of the possible alternative signaling pathways is demonstrated in Fig. 4A. In neutrophils of patients with HC, the failure of PT-sensitive IP_3 and IP_3 -induced Ca^{2+} signals suggest that the AT1 receptor—Gi protein—PLC pathway is injured, and the signaling occurs in part through the opening of the V-sensitive Ca^{2+} channels. As a consequence of altered membrane rigidity and composition in neutrophils of patients with HC, one of the possibilities is a second alternative signaling pathway through the activation of $\text{PI3K-Ins}(3,4,5)\text{P}_3$, the latter being able to trigger translocation of $\text{PKC}\zeta$ into the membrane [40]. On the other hand, in some patients with HC, the increase in the LDL cholesterol level in the serum is caused by the enhancement of endogenous cholesterol synthesis through increased activity of the mevalonate pathway. However, the elevated activity of mevalonate pathway results in an increase in the isoprenylation of Rac2 GTPase and, consequently, NADPH oxidase and PLA_2 activities [6]. In Fig. 4B, the partial restoration of signaling achieved by Flu administration is demonstrated. The inhibition of Rac2 GTPase isoprenylation dramatically decreases NADPH oxidase and PLA_2 activities. In the Flu-treated group, the appearance of either the PT-resistant IP_3 signal or both the V-sensitive and V-insensitive Ca^{2+} signals suggests that the genuine signaling pathway in neutrophils is not restored by Flu therapy. In addition, the partial restoration of membrane-bound PKC activity and the unchanged membrane rigidity can serve as evidence for the existence of alternative signaling [41]. An explanation for the partially restored signaling can be that the PI3K -produced $\text{Ins}(3,4,5)\text{P}_3$ is able to trigger PLC and, consequently, the PT-resistant IP_3 and Ca^{2+} signals [42]. It should be pointed out that we could not exclude other alternative pathways such as signaling through MAP kinase [43,44] or through PT-resistant Gq protein [45]. Finally, it should be noted that membrane-bound cholesterol content and, consequently, membrane fluidity can alter cholecystokinin- β and oxytocin receptor function and that we may not rule out a direct interaction between membrane cholesterol and AII receptors either [46].

Before summarizing the results of our clinical trials, it must be emphasized that these experiments were conducted in a parallel manner and were not set up as self-controlled systems. Consequently, some caution is advisable at their evaluation. We conclude that Flu administration counteracts the AII-triggered enhanced free radical production of neutrophils obtained from patients with HC through the inhibition of Rac2 GTPase. Furthermore, Flu administration has an effect on the signal processing of AII as well as on the enzymes and ion channels, which are in close relationship with the membrane. In spite of the lowering-cholesterol level in plasma and cell membrane, the increased

membrane rigidity remains unchanged after Flu administration, possibly as a consequence of the Flu-resistant phospholipid composition of the cell membrane caused by HC. Therefore, it cannot rule out the possibility that there is a connection between cell membrane rigidity and the altered functions of membrane-bound components of the neutrophils of patients with HC. These components are involved in altered signal processing after AII stimulation, and this altered signal processing cannot be completely restored with Flu administration in patients with HC.

Acknowledgment

This work was supported by a grant from the Hungarian Medical Research Council, Budapest, Hungary, ETT (11AO 24/0003).

References

- [1] Paragh G, Szabo J, Kovacs E, et al. Altered signal pathway in angiotensin II-stimulated neutrophils of patients with hypercholesterolaemia. *Cell Signal* 2002;14:787–92.
- [2] Corsini A. Fluvastatin: effects beyond cholesterol lowering. *J Cardiovasc Pharmacol Ther* 2000;5:161–75.
- [3] Diebold BA, Bhagavan NV, Guillory RJ. Influences of lovastatin administration on the respiratory burst of leukocytes and the phosphorylation potential of mitochondria in guinea pigs. *Biochim Biophys Acta* 1994;1200:100–8.
- [4] Bokoch GM, Diebold BA. Current molecular models for NADPH oxidase regulation by Rac GTPase. *Blood* 2000;100:2692–6.
- [5] Bokoch GM, Knaus UG. NADPH oxidases: not just for leukocytes anymore! *Trends Biochem Sci* 2003;28:502–8.
- [6] Wassmann S, Laufs U, Baumer AT, et al. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cell involvement of angiotensin AT1 receptor expression and Rac1 GTPase. *Mol Pharmacol* 2001;59:646–54.
- [7] Rahman ST, Lauten WB, Khan QA, et al. Effects of eprosartan versus hydrochlorothiazide on markers of vascular oxidation and inflammation and blood pressure (renin-angiotensin system antagonists, oxidation and inflammation). *Am J Cardiol* 2002;89:686–96.
- [8] Dezső B, Fóris G. Effect of angiotensin II on the Fc receptor activity of macrophages. *Immunology* 1981;42:277–83.
- [9] Fóris G, Dezső B, Medgyesi GA, et al. Effect of angiotensin II on macrophage functions. *Immunology* 1983;48:529–35.
- [10] Nickenig G, Roling J, Strehlow K, et al. Insulin induces upregulation of vascular AT1 receptor gene expression by posttranscriptional mechanisms. *Circulation* 1998;98:2453–60.
- [11] Paragh G, Kovacs E, Seres I, et al. Altered signal pathway in granulocytes from patients with hypercholesterolemia. *J Lipid Res* 1999;40:1728–33.
- [12] Boyum A. Isolation of mononuclear cells and granulocytes from human blood. *Scand J Clin Lab Invest* 1968;97:S77–S108.
- [13] Fülöp T, Varga Z, Fóris G, et al. Age-related impairment in phosphatidylinositol breakdown of polymorphonuclear granulocytes. *FEBS Lett* 1989;245:249–52.
- [14] Fülöp T, Varga Z, Foris G, et al. Studies of opsonized zymosan, FMLP, carbachol, PMA and A23187 stimulated respiratory burst of human PMNLs. *Biochem Int* 1988;17:419–26.
- [15] Chodniewicz D, Zhelev D. Chemoattractant receptor-stimulated F-actin polymerization in the human neutrophil is signaled by 2 distinct pathways. *Blood* 2003;101:1181–4.
- [16] van Gilst WH, van Wijngaarden J, Scholtens E, et al. Captopril-induced increase in coronary flow: an SH-dependent effect on arachidonic acid metabolism? *J Cardiovasc Pharmacol* 1987;9:S31–6.

- [17] Yang KD, Augustine NH, Shaio MF, et al. Effects of fibronectin on actin organization and respiratory burst activity in neutrophils, monocytes, and macrophages. *J Cell Physiol* 1994;158:347–53.
- [18] Varga Z, Czompa A, Kakuk G, et al. Inhibition of the superoxide anion release and hydrogen peroxide formation in PMNLs by flavonoligands. *Phytother Res* 2001;15:608–12.
- [19] Babior BM, Kipnes RS, Curnutte JJ, et al. Biological defense mechanism. The production by leukocytes of superoxide, a potential bactericide agent. *J Clin Invest* 1970;52:791–4.
- [20] Jubiz W, Nolan G, Kaltenborn KC, et al. An improved technique for extraction, identification and quantification of leukotrienes. *J Liq Chromatogr* 1985;8:1519–26.
- [21] Shaymann JA, BeMeut DM. An improved technique for extraction, identification and quantification of leukotrienes. *Biochem Biophys Res Commun* 1988;151:114–22.
- [22] McCormach J, Cobbold PH, editors. *Cellular calcium: a practical approach*. Oxford: Oxford University Press; 1991. p. 39–41.
- [23] Bell RM, Hannun Y, Loomish C, et al. Mixed micelle assay of protein kinase C. *Methods Enzymol* 1986;124:353–9.
- [24] Gopalakrishna R, Barsky SH, Thomas TP, et al. Factors influencing chelator stable detergent extractable phorbol diester-induced membrane association of protein kinase C. *J Biol Chem* 1986;261:16438–45.
- [25] Goh EH, Krauth DK, Colles SM, et al. Analysis of cholesterol in cultured cells without solvent extraction. *Lipids* 1990;25:738–45.
- [26] Shinitzky M, Yuli I. Membrane fluidity and cellular functions. In: Shinitzky M, editor. *Physiology of membrane fluidity*, vol. 1. Boca Raton: CPC Press; 1984. p. 1–52.
- [27] Dezso B, Jacobsen J, Poulsen K, et al. Evidence for the presence of angiotensin in normal, unstimulated alveolar macrophages and monocytes. *J Hypertens* 1989;7:5–11.
- [28] Kim JA, Berliner JA, Nadler JL, et al. Angiotensin II increases monocyte binding to endothelial cells. *Biochem Biophys Res Commun* 1996;226:862–8.
- [29] Nickenig G, Bohm M. Regulation of the angiotensin AT1 receptor expression by hypercholesterolemia. *Eur J Med Res* 1997;28:285–9.
- [30] Bromberg Y, Shani E, Joseph G, et al. The GDP-bound form of the small G protein ac1 p21 is a potent activator of the superoxide forming NADPH oxidase of macrophages. *J Biol Chem* 1994;269:7055–8.
- [31] Shin EA, Kim KH, Han SI, et al. Arachidonic acid induces the activation of the stress-activated protein kinase, membrane ruffling and H₂O₂ production via a small GTPase Rac1. *FEBS Lett* 1999;452:355–9.
- [32] Vazquez-Prado J, Casas-Gonzalez P, Garcia-Sainz JA. G protein-coupled receptor cross-talk: pivotal roles of protein phosphorylation and protein-protein interaction. *Cell Signal* 2003;15:549–57.
- [33] Payrastra B, Missy K, Giuriato S, et al. Phosphoinositides: key players in cell signalling, in time and space. *Cell Signal* 2001;13:377–87.
- [34] Kiselyov K, Shin DM, Muallem S. Signalling specificity in GPCR-dependent Ca²⁺ signalling. *Cell Signal* 2003;15:243–53.
- [35] Thekkumkara TJ, Linas SL. Evidence for involvement of 3'-untranslated region in determining angiotensin II receptor coupling specificity to G-protein. *Biochem J* 2003;370:631–9.
- [36] De-Gasparo M. Les recepteurs AT(1) at AT(2) de l' angiotensine II: essential. *Drugs* 2002;1:1–10.
- [37] Touyz RM, Berry C. Recent advances in angiotensin signaling. *Braz J Med Res* 2002;35:1001–15.
- [38] Nixon JB, McPhail LC. Protein kinase C (PKC) isoforms translocate to triton-insoluble fractions in stimulated human neutrophils: correlation of conventional PKC with activation of NADPH oxidase. *J Immunol* 1999;163:4574–82.
- [39] Foris G, Paragh G, Dezso B, et al. Altered postreceptonal transduction of formyl-Met-Leu-Phe receptors in polymorphonuclear leukocytes of patients with non insulin-dependent diabetes mellitus. *Clin Immunol Immunopathol* 1998;86:95–101.
- [40] Keqiang Y, Snyder SH. PIKE GTPase: a novel mediator of phosphoinositide signaling. *J Cell Sci* 2004;117:155–61.
- [41] Momchilova-Pankove AB, Markovska TT, Yanev EI, et al. Phospholipase C activities in rat liver plasma membranes depend on the phospholipid composition. *J Lipid Mediators Cell Signal* 1994;9:235–46.
- [42] Wu D, Huang CK, Jiang H. Roles of phospholipid signaling in chemoattractant-induced responses. *J Cell Sci* 2000;113:2935–40.
- [43] Leever SJ, Vanhasebroeck B, Waterfield MD. Signalling through phosphoinositide 3-kinases: the lipids take centre stage. *Curr Opin Cell Biol* 1999;11:219–25.
- [44] Nixon JB, McPhail LC. Protein kinase C (PKC) isoforms translocate to triton-insoluble fractions in stimulated human neutrophils: correlation of conventional PKC with activation of NADPH oxidase. *J Immunol* 1999;163:4574–82.
- [45] Fields TA, Casey PJ. Signalling functions and biochemical properties of pertussis toxin resistant G-protein. *Biochem J* 1997;321:561–71.
- [46] Politowska E, Kazmierkiewicz R, Wiegand V, et al. Molecular modelling study of the role of cholesterol in the stimulation of the oxytocin receptor. *Acta Biochim Pol* 2001;48:83–93.